Late Breaking Abstract - Protection by budesonide against clinically important deteriorations (CID) in patients with COPD is dependent on blood eosinophil counts (EOS)
Prif Awduron: | Bafadhel, M, Sing, D, Jenkins, C, Peterson, S, Bengtsson, T, Fageras, M |
---|---|
Fformat: | Conference item |
Cyhoeddwyd: |
European Respiratory Society
2018
|
Eitemau Tebyg
-
Adding budesonide to formoterol reduces risk of clinically important deteriorations (CID) in moderate to very severe COPD
gan: Bafadhel, M, et al.
Cyhoeddwyd: (2018) -
Modelling peripheral blood eosinophils to identify response to budesonide in COPD: a post-hoc analysis
gan: Bafadhel, M, et al.
Cyhoeddwyd: (2017) -
Investigating blood eosinophil count thresholds in patients with COPD
gan: Russell, R, et al.
Cyhoeddwyd: (2018) -
Late breaking abstract - Dose-ranging study of mepolizumab in eosinophilic COPD
gan: Pavord, I, et al.
Cyhoeddwyd: (2017) -
Case series of long-term macrolide therapy effect on eosinophil count in COPD
gan: Asciak, R, et al.
Cyhoeddwyd: (2017)